, , and Polymorphisms and Ability to Return to Work in Adult Patients with Low- and High-grade Glioma

Overview

Journal Neurooncol Pract

Publisher Oxford University Press

Date 2019 Sep 27

PMID 31555452

Citations 11

Authors

David B Altshuler

Lin Wang

Lili Zhao

Zachary Miklja

Joey Linzey

Amanda Brezzell

Sofia Kakaizada

Saritha Krishna

Daniel A Orringer

Emily M Briceno

Nicolette Gabel

Shawn L Hervey-Jumper

Affiliations

Soon will be listed here.

Abstract

Background: Cognitive and language dysfunction is common among patients with glioma and has a significant impact on survival and health-related quality of life (HRQOL). Little is known about the factors that make individual patients more or less susceptible to the cognitive sequelae of the disease. A better understanding of the individual and population characteristics related to cognitive function in glioma patients is required to appropriately stratify patients, prognosticate, and develop more efficacious treatment regimens. There is evidence that allelic variation among genes involved in neurotransmission and synaptic plasticity are related to neurocognitive performance in states of health and neurologic disease.

Methods: We studied the association of single-nucleotide polymorphism variations in brain-derived neurotrophic factor (, rs6265), dopamine receptor 2 (, rs1076560), and catechol-O-methyltransferase (, rs4680) with neurocognitive function and ability to return to work in glioma patients at diagnosis and at 3 months. We developed a functional score based on the number of high-performance alleles that correlates with the capacity for patients to return to work.

Results: Patients with higher-performing alleles have better scores on neurocognitive testing with the Repeatable Battery for the Assessment of Neuropsychological Status and Stroop test, but not the Trail Making Test.

Conclusions: A better understanding of the genetic contributors to neurocognitive performance in glioma patients and capacity for functional recovery is necessary to develop improved treatment strategies based on patient-specific factors.

Citing Articles

Prognostic and immunomodulatory roles of schizophrenia-associated genes HTR2A, COMT, and PRODH in pan-cancer analysis and glioma survival prediction model.

Shen J, Wang Q, Lu F, Xu H, Wang P, Feng Y Front Immunol. 2023; 14:1201252.

PMID: 37564635 PMC: 10411190. DOI: 10.3389/fimmu.2023.1201252.

Neurotoxicity from Old and New Radiation Treatments for Brain Tumors.

Soffietti R, Pellerino A, Bruno F, Mauro A, Ruda R Int J Mol Sci. 2023; 24(13).

PMID: 37445846 PMC: 10342178. DOI: 10.3390/ijms241310669.

A Personalized Longitudinal Strategy in Low-Grade Glioma Patients: Predicting Oncological and Neural Interindividual Variability and Its Changes over Years to Think One Step Ahead.

Duffau H J Pers Med. 2022; 12(10).

PMID: 36294760 PMC: 9604939. DOI: 10.3390/jpm12101621.

Influences on cognitive outcomes in adult patients with gliomas: A systematic review.

Kirkman M, Hunn B, Thomas M, Tolmie A Front Oncol. 2022; 12:943600.

PMID: 36033458 PMC: 9407441. DOI: 10.3389/fonc.2022.943600.

Complications, compliance, and undertreatment do not explain the relationship between cognition and survival in diffuse glioma patients.

van Kessel E, Krijnen E, IJpelaar S, Huenges Wajer I, Ruis C, Seute T Neurooncol Pract. 2022; 9(4):284-298.

PMID: 35855455 PMC: 9290897. DOI: 10.1093/nop/npac027.

References

Arbuthnott K, Frank J . Trail making test, part B as a measure of executive control: validation using a set-switching paradigm. J Clin Exp Neuropsychol. 2000; 22(4):518-28. DOI: 10.1076/1380-3395(200008)22:4;1-0;FT518. View

Matzilevich D, Rall J, Moore A, Grill R, Dash P . High-density microarray analysis of hippocampal gene expression following experimental brain injury. J Neurosci Res. 2002; 67(5):646-63. DOI: 10.1002/jnr.10157. View

Scott J, Brasher P, Sevick R, Rewcastle N, Forsyth P . How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. 2002; 59(6):947-9. DOI: 10.1212/wnl.59.6.947. View

Egan M, Kojima M, Callicott J, Goldberg T, Kolachana B, Bertolino A . The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003; 112(2):257-69. DOI: 10.1016/s0092-8674(03)00035-7. View

Uchida K, Baba H, Maezawa Y, Furukawa S, Omiya M, Kokubo Y . Increased expression of neurotrophins and their receptors in the mechanically compressed spinal cord of the spinal hyperostotic mouse (twy/twy). Acta Neuropathol. 2003; 106(1):29-36. DOI: 10.1007/s00401-003-0691-4. View

Taphoorn M, Klein M . Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004; 3(3):159-68. DOI: 10.1016/S1474-4422(04)00680-5. View

Schabitz W, Berger C, Kollmar R, Seitz M, Tanay E, Kiessling M . Effect of brain-derived neurotrophic factor treatment and forced arm use on functional motor recovery after small cortical ischemia. Stroke. 2004; 35(4):992-7. DOI: 10.1161/01.STR.0000119754.85848.0D. View

Tombaugh T . Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004; 19(2):203-14. DOI: 10.1016/S0887-6177(03)00039-8. View

Chafetz M, Matthews L . A new interference score for the Stroop test. Arch Clin Neuropsychol. 2004; 19(4):555-67. DOI: 10.1016/j.acn.2003.08.004. View

10.

de Frias C, Annerbrink K, Westberg L, Eriksson E, Adolfsson R, Nilsson L . COMT gene polymorphism is associated with declarative memory in adulthood and old age. Behav Genet. 2004; 34(5):533-9. DOI: 10.1023/B:BEGE.0000038491.06972.8c. View

11.

Krabbe K, Nielsen A, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C . Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia. 2006; 50(2):431-8. DOI: 10.1007/s00125-006-0537-4. View

12.

Hunnerkopf R, Strobel A, Gutknecht L, Brocke B, Lesch K . Interaction between BDNF Val66Met and dopamine transporter gene variation influences anxiety-related traits. Neuropsychopharmacology. 2007; 32(12):2552-60. DOI: 10.1038/sj.npp.1301383. View

13.

Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R . Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci U S A. 2007; 104(51):20552-7. PMC: 2154469. DOI: 10.1073/pnas.0707106104. View

14.

Cramer S . A window into the molecular basis of human brain plasticity. J Physiol. 2008; 586(23):5601. PMC: 2655405. DOI: 10.1113/jphysiol.2008.165183. View

15.

Matthews V, Astrom M, Chan M, Bruce C, Krabbe K, Prelovsek O . Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase. Diabetologia. 2009; 52(7):1409-18. DOI: 10.1007/s00125-009-1364-1. View

16.

Hyman C, Hofer M, Barde Y, Juhasz M, Yancopoulos G, Squinto S . BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature. 1991; 350(6315):230-2. DOI: 10.1038/350230a0. View

17.

Correa D . Neurocognitive function in brain tumors. Curr Neurol Neurosci Rep. 2010; 10(3):232-9. DOI: 10.1007/s11910-010-0108-4. View

18.

Pearson-Fuhrhop K, Cramer S . Genetic influences on neural plasticity. PM R. 2010; 2(12 Suppl 2):S227-40. DOI: 10.1016/j.pmrj.2010.09.011. View

19.

Small B, Rawson K, Walsh E, Jim H, Hughes T, Iser L . Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer. 2011; 117(7):1369-76. DOI: 10.1002/cncr.25685. View

20.

Bleeker F, Molenaar R, Leenstra S . Recent advances in the molecular understanding of glioblastoma. J Neurooncol. 2012; 108(1):11-27. PMC: 3337398. DOI: 10.1007/s11060-011-0793-0. View